Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

التفاصيل البيبلوغرافية
العنوان:	Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
المؤلفون:	Reck, Martin, Mok, Tony SK, Nishio, Makoto, Jotte, Robert M, Cappuzzo, Federico, Orlandi, Francisco, Stroyakovskiy, Daniil, Nogami, Naoyuki, Rodríguez-Abreu, Delvys, Moro-Sibilot, Denis, Thomas, Christian A, Barlesi, Fabrice, Finley, Gene, Lee, Anthony, Coleman, Shelley, Deng, Yu, Kowanetz, Marcin, Shankar, Geetha, Lin, Wei, Socinski, Mark A, Mok, Tony S K
المصدر:	In The Lancet Respiratory Medicine May 2019 7(5):387-401
قاعدة البيانات:	ScienceDirect

الوصف
تدمد:	22132600
DOI:	10.1016/S2213-2600(19)30084-0